Amgen's MariTide: A Potential Game-Changer in the Fight Against Obesity
Amgen's Catching Up to Novo Nordisk and Eli Lilly
The gold rush for obesity medications just got a bit more intense. With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by the likes of Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO).
This candidate could give Eli Lilly and Novo Nordisk a run for their money
Amgen's entrant in the weight-loss drug gold rush is called MariTide, and it's currently in phase 2 clinical trials. Thanks to how favorable the preliminary phase 2 data is, management is already planning on a phase 3 trial that aims to investigate the candidate's utility in treating obesity-adjacent cardiometabolic conditions like type 2 diabetes.
The balance of risk and reward is appealing at the moment
Per Fortune Business Insights, the global market for anti-obesity medicines will be worth as much as $37.9 billion by 2032, up from around $4.5 billion in 2023. On the basis of the available information so far, it is probable that Amgen can secure an economically meaningful portion of the market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.